Form 8-K Summary
Company: Pliant Therapeutics, Inc. (Nasdaq: PLRX)
Report date: May 4, 2022
Primary event: Entry into a material Loan and Security Agreement with Oxford Finance LLC.
Business Context and Reporting Period
The filing reports a new secured debt facility intended to provide working capital and fund general corporate requirements, including development activities for PLN-74809 and a preclinical product candidate. The filing does not report operating results for a quarterly or annual period.
Financing and Key Financial Terms
- Total potential term-loan commitments are up to $100.0 million, including $25.0 million subject to the lender’s sole discretion.
- The company drew an initial $10.0 million of a $25.0 million initial tranche at closing. The remaining $15.0 million was available through the end of 2022, subject to the agreement’s conditions.
- An additional $75.0 million is available in three tranches. $50.0 million is exercisable by the company upon satisfaction of development-related conditions, while $25.0 million is subject to lender discretion.
- Interest accrues at one-month term SOFR plus 8.50%, subject to an agreed floor and cap, and is payable monthly beginning July 1, 2022.
- Scheduled principal amortization begins July 1, 2026, with a possible extension to July 1, 2027, subject to specified conditions.
- All outstanding principal and accrued interest is due May 1, 2027, with a possible extension to May 1, 2028.
- A final payment equal to 5.50% of the original principal drawn is due at maturity or earlier acceleration or prepayment. The final payment increases to 7.50% if amortization is extended to July 1, 2027.
- Funded term loans incur a 0.5% facility fee.
- Voluntary prepayments are subject to fees of 3.0%, 2.0%, or 1.0%, depending on the timing of repayment.
- The obligations are secured by substantially all company assets, excluding intellectual property itself but including related payment rights and proceeds. The agreement also includes a negative pledge covering substantially all intellectual property of the company and its subsidiaries.
Material Changes Versus the Prior Comparable Period
The filing text does not provide a prior-period comparison. The material change disclosed is the creation of a new secured borrowing facility and the initial $10.0 million debt draw.
Outlook, Covenants, Risks, and Unusual Items
- Proceeds may be used for working capital and general business purposes in accordance with the agreement.
- The agreement contains customary representations, warranties, affirmative covenants, negative covenants, and events of default.
- An event of default could accelerate repayment, terminate remaining commitments, and permit foreclosure on pledged collateral.
- During an event of default, the interest rate increases by 5 percentage points above the otherwise applicable rate.
- The facility increases financial obligations and exposes the company to variable-rate interest expense based on SOFR. The filing does not provide a specific SOFR floor or cap.
- The company’s ability to access certain future tranches depends on development-related conditions, and some commitments remain subject to lender discretion.
Important Facts for Investors to Verify
- Whether the company draws the remaining initial $15.0 million and any additional tranches.
- The applicable SOFR floor and cap and the resulting effective interest rate.
- Compliance with development conditions required to access the optional $50.0 million tranche.
- Cash balances, cash burn, and the company’s ability to meet interest, amortization, and final-payment obligations.
- The full covenant package, collateral provisions, and events of default in Exhibit 10.1.
- The filing does not provide revenue, profit, cash-flow, margin, or liquidity figures; those amounts should be verified in the company’s applicable periodic financial statements.